Moderna (NASDAQ:MRNA) Issues Quarterly Earnings Results

Moderna (NASDAQ:MRNA - Get Free Report) issued its earnings results on Thursday. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92, Briefing.com reports. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the prior year, the business posted ($1.39) EPS. The company's revenue for the quarter was up 3.8% on a year-over-year basis.

Moderna Stock Performance

NASDAQ MRNA traded down $3.45 on Friday, hitting $46.83. 13,561,538 shares of the company's stock were exchanged, compared to its average volume of 4,882,079. The firm has a market cap of $18.00 billion, a price-to-earnings ratio of -3.04 and a beta of 1.69. The firm's 50-day moving average price is $61.85 and its two-hundred day moving average price is $99.16. Moderna has a fifty-two week low of $46.57 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the company's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company's stock, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,184 shares of company stock valued at $238,531 in the last three months. 15.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have issued reports on MRNA. Bank of America decreased their price objective on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research note on Friday, September 13th. HSBC raised Moderna from a "reduce" rating to a "hold" rating and set a $82.00 target price for the company in a report on Wednesday, August 28th. Needham & Company LLC restated a "hold" rating on shares of Moderna in a research note on Friday. JPMorgan Chase & Co. reduced their price objective on Moderna from $70.00 to $59.00 and set an "underweight" rating for the company in a research note on Monday, November 4th. Finally, UBS Group decreased their price objective on Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $93.18.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.